Fisetin Nanotherapeutics for Cancer Prevention and Treatment: Bioavailability, Preclinical Efficacy, and Translational Challenges
Pharmaceutics · 18.11.2026 · 18 (11) · 1491
DOI: 10.3390/pharmaceutics18111491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.11.2026. Verfasst von Md. Abul Barkat und 9 weiteren Autor:innen. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fisetin, a polyphenolic compound derived from Venetian sumach (Rhus cotinus L.), exhibits notable antioxidant, neuroprotective, anti-inflammatory, and senolytic effects. The compound Fisetin is a secondary metabolite. Chemically, it is known as 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one, 3,3′,4′,7-tetrahydroxyflavone, or 5-deoxy quercetin. Presently, it is obtained from various plants. This bioactive molecule is also reported to exhibit anticancer potential, and researchers have shown promising activity in the management of various cancers, including oral, breast, lung, and brain cancers, as well as other malignancies. Despite holding significant promise, as with other natural compounds, this molecule is associated with challenges such as poor aqueous solubility, compromised bioavailability, greater lipophilicity, and uneven pharmacokinetic distribution. This review highlights the research-based evidence for Fisetin in cancer treatment and emphasizes nanotechnology-based approaches employing this bioactive molecule across various cancers. Examining fisetin’s clinical trials helps chart its evolution from a dietary supplement to a promising anticancer drug.
Zitieren
APA
Barkat, M. A., Alanezi, A. A., Turki, A., Almuqati, A. F., Barkat, H., Alhodieb, F. S., Ansari, M. A., Sarwar, T., Alharbi, H. O. A., & Rahmani, A. H. (2026). Fisetin Nanotherapeutics for Cancer Prevention and Treatment: Bioavailability, Preclinical Efficacy, and Translational Challenges. Pharmaceutics, 18(11), 1491. https://doi.org/10.3390/pharmaceutics18111491
Vancouver
Barkat MA, Alanezi AA, Turki A, Almuqati AF, Barkat H, Alhodieb FS, et al. Fisetin Nanotherapeutics for Cancer Prevention and Treatment: Bioavailability, Preclinical Efficacy, and Translational Challenges. Pharmaceutics. 2026;18(11):1491. doi:10.3390/pharmaceutics18111491
BibTeX
@article{Barkat2026,
author = {Barkat, Md. Abul and Alanezi, Abdulkareem A. and Turki, Abrar and Almuqati, Afaf F. and Barkat, Harshita and Alhodieb, Fahad Saad and Ansari, Mohammad Azam and Sarwar, Tarique and Alharbi, Hajed Obaid A. and Rahmani, Arshad Husain},
title = {Fisetin Nanotherapeutics for Cancer Prevention and Treatment: Bioavailability, Preclinical Efficacy, and Translational Challenges},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1491},
doi = {10.3390/pharmaceutics18111491}
}
EUVIMED